Major depressive disorder is the most common psychiatric disorder, worldwide, yet response and remission rates are still unsatisfactory. The identification of genetic predictors of antidepressant (AD) response could provide a promising opportunity to improve current AD efficacy through the personalization of treatment. The major steps and findings along this path are reviewed together with their clinical implications and limitations.
Method:
We systematically reviewed the literature through MEDLINE and Embase database searches, using any word combination of “antidepressant,” “gene,” “polymorphism,” “pharmacogenetics,” “genome-wide association study,” “GWAS,” “response,” and “adverse drug reactions.” Experimental works and reviews published until March 2012 were collected and compared.
Results:
Numerous genes pertaining to several functional systems were associated with AD response. The more robust findings were found for the following genes: solute carrier family 6 (neurotransmitter transporter), member 4; serotonin receptor 1A and 2A; brain-derived neurotrophic factor; and catechol-O-methyltransferase. Genome-wide association studies (GWASs) provided many top markers, even if none of them reached genome-wide significance.
Conclusions:
AD pharmacogenetics have not produced any knowledge applicable to routine clinical practice yet, as results were mainly inconsistent across studies. Despite this, the rising awareness about methodological deficits of past studies could allow for the identication of more suitable strategies, such as the integration of the GWAS approach with the candidate gene approach, and innovative methodologies, such as pathway analysis and study of depressive endophenotypes.
SerrettiAFranchiniLGasperiniM, Mode of inheritance in mood disorders families according to fluvoxamine response. Acta Psychiatr Scand. 1998;98(6):443–450.
2.
PorcelliSFabbriCDragoA, Genetics and antidepressants: Where we are. Clin Neuropsychiatry. 2011;7:99–150.
3.
PorcelliSFabbriCSerrettiA.Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol. 2012;22(4):239–258.
4.
SlatteryDAHudsonALNuttDJ. Invited review: The evolution of antidepressant mechanisms. Fundam Clin Pharmacol. 2004;18(1):1–21.
5.
HeilsATeufelAPetriS, Allelic variation of human serotonin trasporter gene expression. J Neurochem. 1996;66(6):2621–2624.
6.
SerrettiAMandelliLLorenziC, Temperament and character in mood disorders: Influence of DRD4, SERTPR, TPH and MAO-A polymorphisms. Neuropsychobiology. 2006;53(1):9–16.
7.
KunugiHHattoriMKatoT, Serotonin transporter gene polymorphisms: Ethnic difference and possible association with bipolar affective disorder. Mol Psychiatry. 1997;2(6):457–462.
8.
SerrettiAKatoMDe RonchiD, Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry. 2007;12(3):247–257.
9.
TaylorMJSenSBhagwagarZ.Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biol Psychiatry. 2010;68(6):536–543.
10.
EhliEAHuYLengyel-NelsonT, Identification and functional characterization of three novel alleles for the serotonin transporter-linked polymorphic region. Mol Psychiatry. 2012;17(2):185–192.
11.
PorcelliSDragoAFabbriC, Pharmacogenetics of antidepressant response. J Psychiatry Neurosci. 2011;36(2):87–113.
12.
BaffaAHohoffCBauneBT, Norepinephrine and serotonin transporter genes: Impact on treatment response in depression. Neuropsychobiology. 2010;62(2):121–131.
13.
SerrettiACalatiRMandelliM, Serotonin transporter gene variants and behavior: A comprehensive review. Curr Drug Targets. 2006;7(12):1659–1669.
14.
PerezVGilaberteIFariesD, Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet. 1997;349:1594–1597.
15.
AlbertPRLemondeS.5-HT1A receptors, gene repression, and depression: Guilt by association. Neuroscientist. 2004;10(6):575–593.
16.
BauneBTHohoffCRoehrsT, Serotonin receptor 1A-1019C/G variant: Impact on antidepressant pharmacoresponse in melancholic depression?Neurosci Lett. 2008;436(2):111–115.
17.
NewtonRAPhippsSLFlaniganTP, Characterisation of human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors expressed in the human neuroblastoma cell line SH-SY5Y: Comparative stimulation by hallucinogenic drugs. J Neurochem. 1996;67(6):2521–2531.
18.
MajJBijakMDziedzicka-WasylewskaM, The effects of paroxetine given repeatedly on the 5-HT receptor subpopulations in the rat brain. Psychopharmacology (Berl). 1996;127(1):73–82.
19.
MeyerJHKapurSEisfeldB, The rffect of paroxetine on 5-HT(2A) receptors in depression: An [(18)F]setoperone PET imaging study. Am J Psychiatry. 2001;158:78–85.
20.
SpurlockGHeilsAHolmansP, A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Mol Psychiatry. 1998;3(1):42–49.
21.
LinEChenPSChangHH, Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(7):1167–1172.
22.
SakowskiSAGeddesTJThomasDM, Differential tissue distribution of tryptophan hydroxylase isoforms 1 and 2 as revealed with monospecific antibodies. Brain Res. 2006;1085(1):11–18.
ZhangXGainetdinovRRBeaulieuJ-M, Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron. 2005;45(1):11–16.
25.
LimJEPinsonneaultJSadeeW, Tryptophan hydroxylase 2 (TPH2) haplotypes predict levels of TPH2 mRNA expression in human pons. Mol Psychiatry. 2007;12(5):491–501.
26.
WeinshilboumRMOtternessDMSzumlanskiCL. Methylation pharmacogenetics: Catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol. 1999;39:19–52.
27.
AriasBSerrettiALorenziC, Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J Affect Disord. 2006;90(2–3):251–256.
28.
SabolSZHuSHamerD.A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet. 1998;103:273–279.
29.
JonssonEGNortonNGustavssonJP, A promoter polymorphism in the monoamine oxidase A gene and its relationships to monoamine metabolite concentrations in CSF of healthy volunteers. J Psychiatr Res. 2000;34(3):239–244.
30.
TadicAMullerMJRujescuD, The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. Am J Med Genet B Neuropsychiatr Genet. 2007;144(3):325–331.
31.
TzengDSChienCCLungFW, MAOA gene polymorphisms and response to mirtazapine in major depression. Hum Psychopharmacol. 2009;24(4):293–300.
32.
McClureDJ. The role of dopamine in depression. Can Psychiatr Assoc J. 1973;18(4):309012.
33.
WillnerP.Dopamine and depression: A review of recent evidence. I. Empirical studies. Brain Res. 1983;287(3):211–224.
DaillyEChenuFRenardCE, Dopamine, depression and antidepressants. Fundam Clin Pharmacol. 2004;18(6):601–607.
36.
PorcelliSDragoAFabbriC, Mechanisms of antidepressant action: An integrated dopaminergic perspective. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(7):1532–1543.
37.
PerlisRHAdamsDHFijalB, Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression. J Clin Psychiatry. 2010;71(5):599–605.
38.
HolsboerF.The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. 2000;23(5):477–501.
39.
NemeroffCBOwensMJ. Treatment of mood disorders. Nat Neurosci. 2002;5(Suppl):1068–1070.
40.
LicinioJO'KirwanFIrizarryK, Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol Psychiatry. 2004;9:1075–1082.
41.
LiuZZhuFWangG, Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci Lett. 2007;414(2):155–158.
42.
PapiolSAriasBGastoC, Genetic variability at H PA axis in major depression and clinical response to antidepressant treatment. J Affect Disord. 2007;104(1–3):83–90.
43.
BinderEBOwensMJLiuW, Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. Arch Gen Psychiatry. 2010;67(4):369–379.
44.
PrattWBMorishimaYMurphyM, Chaperoning of glucocorticoid receptors. Handb Exp Pharmacol. 2006;(172):111–138.
45.
BinderEB. The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology. 2009;34(Suppl 1):S186–S195.
46.
BinderEBSalyakinaDLichtnerP, Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet. 2004;36(12):1319–1325.
47.
KirchheinerJLorchRLebedevaR, Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics. 2008;9(7):841–846.
48.
LekmanMLajeGCharneyD, The FKBP5-gene in depression and treatment response—an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) cohort. Biol Psychiatry. 2008;63(12):1103–1110.
49.
BrunoniARLopesMFregniF.A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: Implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol. 2008;11(8):1169–1180.
50.
MandelliLMazzaMMartinottiG, Further evidence supporting the influence of brain-derived neurotrophic factor on the outcome of bipolar depression: Independent effect of brain-derived neurotrophic factor and harm avoidance. J Psychopharmacol. 2010;24(12):1747–1754.
51.
PetryshenTLSabetiPCAldingerKA, Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. Mol Psychiatry. 2010;15(8):810–815.
52.
DongCWongMLLicinioJ.Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: Association with major depression and antidepressant response in Mexican-Americans. Mol Psychiatry. 2009;14(12):1105–1118.
53.
ChenGHasanatKABebchukJM, Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants. Psychosom Med. 1999;61(5):599–617.
54.
Ruiz-VelascoVIkedaSR. A splice variant of the G protein beta 3-subunit implicated in disease states does not modulate ion channels. Physiol Genomics. 2003;13(2):85–95.
55.
PaddockSLajeGCharneyD, Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry. 2007;164(8):1181–1188.
56.
HorstmannSLucaeSMenkeA, Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology. 2010;35(3):727–740.
57.
HorstmannSLucaeSMenkeA, Association of GRIK4 and HTR2A genes with antidepressant treatment in the MARS cohort of depressed inpatients. Eur Neuropsychopharmacol. 2008;18:S214–S215.
58.
LajeGPaddockSManjiH, Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry. 2007;164(10):1530–1538.
59.
PerlisRHLajeGSmollerJW, Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. Neuropsychopharmacology. 2009;34(7):1819–1828.
60.
Cordon-CardoCO'BrienJPCasalsD, Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A. 1989;86(2):695–698.
61.
EichelbaumMFrommMFSchwabM.Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit. 2004;26(2):180–185.
62.
KatoMFukudaTSerrettiA, ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):398–404.
63.
NikischGEapCBBaumannP.Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: A pilot study. Pharmacol Res. 2008;58(5–6):344–347.
64.
SarginsonJELazzeroniLCRyanHS, ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. Pharmacogenet Genomics. 2010;20(8):467–475.
65.
UhrMTontschANamendorfC, Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008;57(2):203–209.
66.
LaikaBLeuchtSSteimerW.ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): Lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline. Clin Chem. 2006;52(5):893–895.
67.
PetersEJSlagerSLKraftJB, Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLOS ONE. 2008;3(4):e1872.
68.
Mihaljevic PelesABozinaNSagudM, MDR1 gene polymorphism: Therapeutic response to paroxetine among patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(6):1439–1444.
69.
PorcelliSFabbriCSpinaE, Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. Expert Opin Drug Metab Toxicol. 2011;7(9):1101–1115.
70.
de LeonJArmstrongSCCozzaKL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics. 2006;47(1):75–85.
71.
KirchheinerJSeeringerA.Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta. 2007;1770(3):489–494.
72.
de LeonJSusceMTMurray-CarmichaelE.The AmpliChip CYP450 genotyping test: Integrating a new clinical tool. Mol Diagn Ther. 2006;10(3):135–151.
73.
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: Testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med. 2007;9(12):819–825.
74.
Psychiatric GWAS Consortium Steering Committee. A framework for interpreting genome-wide association studies of psychiatric disorders. Mol Psychiatry. 2009;14(1):10–17.
75.
Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447(7145):661–678.
76.
GarriockHAKraftJBShynSI, A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry. 2010;67(2):133–138.
77.
UherRPerroudNNgMY, Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry. 2010;167(5):555–564.
78.
IsingMLucaeSBinderEB, A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry. 2009;66(9):966–975.
79.
O'DonovanMCCraddockNJOwenMJ. Genetics of psychosis; insights from views across the genome. Hum Genet. 2009;126(1):3–12.
80.
National Institute of Mental Health (NIMH)Center for Collaborative Genomics Research on Mental Disorders. NIMH respository and genomics resource (RGR) [Internet]. St Louis (MO): NIMH-RGR; 2009–2013 [cited 2013 Jun 27]. Available from: http://nimhgenetics.org.
81.
LajeGMcMahonFJ. Genome-wide association studies of antidepressant outcome: A brief review. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(7):1553–1557.
82.
SerrettiAKatoMKennedyJL. Pharmacogenetic studies in depression: A proposal for methodologic guidelines. Pharmacogenomics J. 2008;8(2):90–100.
83.
DragoACrisafulliCSerrettiA.The genetics of antipsychotic induced tremors: A genome-wide pathway analysis on the STEP-BD SCP sample. Am J Med Genet B Neuropsychiatr Genet. 2011;156B(8):975–986.
84.
SlodkowskaEARossJS. MammaPrint 70-gene signature: Another milestone in personalized medical care for breast cancer patients. Expert Rev Mol Diagn. 2009;9(5):417–422.
85.
PaikSTangGShakS, Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726–3734.
86.
LinPIVanceJMPericak-VanceMA, No gene is an island: The flip-fop phenomenon. Am J Hum Genet. 2007;80(3):531–538.
87.
HolmansP.Statistical methods for pathway analysis of genome-wide data for association with complex genetic traits. Adv Genet. 2010;72:141–179.
88.
GottesmanIIGouldTD. The endophenotype concept in psychiatry: Etymology and strategic intentions. Am J Psychiatry. 2003;160(4):636–645.
89.
HaslerGDrevetsWCManjiHK, Discovering endophenotypes for major depression. Neuropsychopharmacology. 2004;29(10):1765–1781.
90.
GotlibIHHamiltonJP. Bringing genetics back to psychiatric endophenotypes. Biol Psychiatry. 2012;71(1):2–3.
91.
GlahnDCCurranJEWinklerAM, High dimensional endophenotype ranking in the search for major depression risk genes. Biol Psychiatry. 2012;71(1):6–14.
92.
AriasBCatalanRGastoC, 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol. 2003;23(6):563–567.
93.
SmitsKMSmitsLJPeetersFP, The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients. Psychiatr Genet. 2008;18(4):184–190.
94.
DurhamLKWebbSMMilosPM, The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl). 2004;174(4):525–529.
95.
JoycePRMulderRTLutySE, Age-dependent antidepressant pharmacogenomics: Polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol. 2003;6(4):339–346.
96.
MaronETammisteAKallassaluK, Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. Eur Neuropsychopharmacol. 2009;19(6):451–456.
97.
PerlisRHMischoulonDSmollerJW, Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry. 2003;54(9):879–883.
98.
PollockBGFerrellREMulsantBH, Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology. 2000;23(5):587–590.
99.
RauschJLJohnsonMEFeiY-J, Initial conditions of serotonin transporter kinetics and genotype: Influence on SSRI treatment trial outcome. Biol Psychiatry. 2002;51(9):723–732.
100.
SmeraldiEZanardiRBenedettiF, Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry. 1998;3(6):508–511.
101.
ZanardiRBenedettiFDiBellaD, Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of serotonin transporter gene. J Clin Psychopharmacol. 2000;20(1):105–107.
102.
ZanardiRSerrettiARossiniD, Factors affecting fluvoxamine antidepressant activity: Influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry. 2001;50(5):323–330.
103.
SerrettiACusinCRossiniD, Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. Am J Med Genet B Neuropsychiatr Genet. 2004;129(1):36–40.
104.
PetersEJSlagerSLMcGrathPJ, Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry. 2004;9(9):879–889.
105.
KraftJBSlagerSMcGrathP, Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry. 2005;58(5):374–381.
106.
HuXZRushAJCharneyD, Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry. 2007;64(7):783–792.
107.
BozinaNPelesAMSagudM, Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder. World J Biol Psychiatry. 2008;9(3):190–197.
108.
LotrichFEPollockBGKirshnerM, Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients. J Psychiatry Neurosci. 2008;33(2):123–130.
109.
Huezo-DiazPUherRSmithR, Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry. 2009;195(1):30–38.
110.
MrazekDARushAJBiernackaJM, SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet. 2009;150B(3):341–351.
111.
RuheHGOotemanWBooijJ, Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder. Pharmacogenet Genomics. 2009;19(1):67–76.
112.
IlliAPoutanenOSetälä-SoikkeliE, Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD?Eur Arch Psychiatry Clin Neurosci. 2011;261(2):95–102.
113.
KimDKLimSWLeeS, Serotonin transporter gene polymorphism and antidepressant response. Neuroreport. 2000;11(1):215–219.
114.
YoshidaKItoKSatoK, Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(2):383–386.
115.
YuYWTsaiSJChenTJ, Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry. 2002;7(10):1115–1119.
116.
LeeMSLeeHYLeeHJ, Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment. Psychiatr Genet. 2004;14(2):111–115.
117.
KatoMIkenagaYWakenoM, Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int Clin Psychopharmacol. 2005;20(3):151–156.
118.
HongCJChenTJYuYW, Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J. 2006;6(1):27–33.
119.
KatoMFukudaTWakenoM, Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology. 2006;53(4):186–195.
120.
KimHLimSWKimS, Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA. 2006;296(13):1609–1618.
121.
Umene-NakanoWYoshimuraRUedaN, Predictive factors for responding to sertraline treatment: Views from plasma catecholamine metabolites and serotonin transporter polymorphism. J Psychopharmacol. 2010;24(12):1764–1771.
122.
DoganOYukselNErgunMA, Serotonin transporter gene polymorphisms and sertraline response in major depression patients. Genet Test. 2008;12(2):225–231.
123.
LewisGMulliganJWilesN, Polymorphism of the 5-HT transporter and response to antidepressants: Randomised controlled trial. Br J Psychiatry. 2011;198(6):464–471.
124.
NgCHEastealSTanS, Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(5):953–957.
125.
YoshimuraRUmene-NakanoWSuzukiA, Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients. Hum Psychopharmacol. 2009;24(6):489–494.
126.
SmitsKSmitsLPeetersF, Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. Int Clin Psychopharmacol. 2007;22(3):137–143.
127.
ReimherrFAmsterdamJDunnerD, Genetic polymorphisms in the treatment of depression: Speculations from an augmentation study using atomoxetine. Psychiatry Res. 2010;175(1–2):67–73.
128.
MurataYKobayashiDImutaN, Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. J Clin Psychopharmacol. 2010;30(1):11–17.
129.
TakahashiHYoshidaKItoK, No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment. Eur Neuropsychopharmacol. 2002;12(5):477–481.
130.
TanakaMKobayashiDMurakamiY, Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. Int J Neuropsychopharmacol. 2008;11(2):261–267.
131.
BishopJREllingrodVLAkroushM, The association of serotonin transporter genotypes and selective serotonin reuptake inhibitor (SSRI)-associated sexual side effects: Possible relationship to oral contraceptives. Hum Psychopharmacol. 2009;24(3):207–215.
132.
KirchheinerJNickchenKSasseJ, A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. Pharmacogenomics J. 2007;7(1):48–55.
133.
MurphyGMJrHollanderSBRodriguesHE, Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry. 2004;61(11):1163–1169.
134.
MinovCBaghaiTCSchuleC, Serotonin-2A-receptor and -transporter polymorphisms: Lack of association in patients with major depression. Neurosci Lett. 2001;303(2):119–122.
135.
WilkieMJSmithGDayRK, Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics J. 2009;9(1):61–70.
KangR-HWongM-LChoiM-J, Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(6):1317–1321.
138.
MinWLiTMaX, Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response. Psychopharmacology (Berl). 2009;205(3):409–417.
139.
LeeSHChoiTKLeeE, Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine. Neuropsychobiology. 2010;62(3):198–206.
140.
BukhJDBockCVinbergM, Interaction between genetic polymorphisms and stressful life events in first episode depression. J Affect Disord. 2009;119(1–3):107–115.
141.
YoshidaKTakahashiHHiguchiH, Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry. 2004;161(9):1575–1580.
142.
PoppJLeuchtSHeresS, Serotonin transporter polymorphisms and side effects in antidepressant therapy—a pilot study. Pharmacogenomics. 2006;7(2):159–166.
143.
SecherABukhJBockC, Antidepressive-drug-induced bodyweight gain is associated with polymorphisms in genes coding for COMT and TPH1. Int Clin Psychopharmacol. 2009;24(4):199–203.
144.
StrohmaierJWüstSUherR, Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: Clinical description and the role of the 5-HTTLPR. World J Biol Psychiatry. 2011;12(7):528–538.
145.
HiguchiHTakahashiHKamataM, Influence of serotonergic/noradrenergic gene polymorphisms on nausea and sweating induced by milnacipran in the treatment of depression. Neuropsychiatr Dis Treat. 2009;5:393–398.
146.
StammTJAdliMKirchheinerJ, Serotonin transporter gene and response to lithium augmentation in depression. Psychiatr Genet. 2008;18(2):92–97.
147.
ItoKYoshidaKSatoK, A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res. 2002;111(2–3):235–239.
148.
KraftJBPetersEJSlagerSL, Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry. 2007;61(6):734–742.
149.
SerrettiAArtioliPLorenziC, The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: Preliminary findings. Int J Neuropsychopharmacol. 2004;7(4):453–460.
150.
AriasBCatalanRGastoC, Evidence for a combined genetic effect of the 5-HT1A receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram. J Psychopharmacol. 2005;19(2):166–172.
151.
YuYWTsaiSJLiouYJ, Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. Eur Neuropsychopharmacol. 2006;16(7):498–503.
152.
KatoMFukudaTWakenoM, Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. Am J Med Genet B Neuropsychiatr Genet. 2009;150B(1):115–123.
153.
VillafuerteSMVallabhaneniKSliwerskaE, SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A. Psychiatr Genet. 2009;19(6):281–291.
154.
IlliASetala-SoikkeliEViikkiM, 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport. 2009;20(12):1125–1128.
155.
LevinGMBowlesTMEhretMJ, Assessment of human serotonin 1A receptor polymorphisms and SSRI responsiveness. Mol Diagn Ther. 2007;11(3):155–160.
156.
NoroMAntonijevicIForrayC, 5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder. Int Clin Psychopharmacol. 2010;25(4):228–231.
157.
LemondeSDuLBakishD, Association of the C(1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Int J Neuropsychopharmacol. 2004;7(4):501–506.
158.
XuZZhangZShiY, Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response. J Psychopharmacol. 2012;26(3):349–359.
159.
SuzukiYSawamuraKSomeyaT.The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients. Pharmacoeconomics J. 2004;4(4):283–286.
160.
TsaiSJHongCJYuYW, Association study of serotonin 1B receptor (A-161T) genetic polymorphism and suicidal behaviors and response to fluoxetine in major depressive disorder. Neuropsychobiology. 2004;50(3):235–238.
161.
ChoiMKangRHamB, Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram. Neuropsychobiology. 2005;52:155–162.
162.
SatoKYoshidaKTakahashiH, Association between −1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology. 2002;46(3):136–140.
163.
SuzukiYSawamuraKSomeyaT.Polymorphisms in the 5-hydroxytryptamine 2A receptor and cytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in Japanese depressed patients. Neuropsychopharmacology. 2006;31(4):825–831.
164.
BishopJRMolineJEllingrodVL, Serotonin 2A −1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology. 2006;31(10):2281–2288.
165.
YoshidaKNaitoSTakahashiH, Monoamine oxidase A gene polymorphism, 5-HT 2A receptor gene polymorphism and incidence of nausea induced by fluvoxamine. Neuropsychobiology. 2003;48(1):10–13.
166.
KangRHChoiMJPaikJW, Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression. Int J Psychiatry Med. 2007;37(3):315–329.
167.
CusinCSerrettiAZanardiR, Influence of monoamine oxydase A and serotonin receptor 2A polymorphisms in SSRIs antidepressant activity. Int J Neuropsychopharmacol. 2002;5:27–35.
168.
MurphyGMJrHollanderSBRodriguesHE, Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry. 2004;61(11):1163–1169.
169.
PetersEJSlagerSLJenkinsGD, Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. Pharmacogenet Genomics. 2009;19(1):1–10.
170.
McMahonFJBuervenichSCharneyD, Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006;78(5):804–814.
171.
LucaeSIsingMHorstmannS, HTR2A gene variation is involved in antidepressant treatment response. Eur Neuropsychopharmacol. 2010;20(1):65–68.
172.
PerlisRHFijalBAdamsDH, Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biol Psychiatry. 2009;65(9):785–791.
173.
KishiTYoshimuraRKitajimaT, HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort. Neuromolecular Med. 2010;12(3):237–242.
174.
UherRHuezo-DiazPPerroudN, Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J. 2009;9(4):225–233.
175.
SugaiTSuzukiYSawamuraK, The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine. Pharmacogenomics J. 2006;6(5):351–356.
176.
KishiTFukuoYYoshimuraR, Pharmacogenetic study of serotonin 6 receptor gene with antidepressant response in major depressive disorder in the Japanese population. Hum Psychopharmacol. 2010;25(6):481–486.
177.
LeeSLeeKLeeH, Association between the 5-HT6 receptor C267T polymorphism and response to antidepressant treatment in major depressive disorder. Psychiatry Clin Neurosci. 2005;59:140–145.
178.
WuWHHuoSJChengCY, Association study of the 5-HT(6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders. Neuropsychobiology. 2001;44(4):172–175.
179.
HamBJLeeBCPaikJW, Association between the tryptophan hydroxylase−1 gene A218C polymorphism and citalopram antidepressant response in a Korean population. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(1):104–107.
SerrettiAZanardiRRossiniD, Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry. 2001;6:586–592.
182.
ViikkiMKampmanOIlliA, TPH1 218A/C polymorphism is associated with major depressive disorder and its treatment response. Neurosci Lett. 2010;468:80–84.
183.
HamBLeeMLeeM, No association between the tryptophan hydroxylase gene polymorphism and major depressive disorders and antidepressant response in a Korean population. Psychiatr Genet. 2005;15(4):229–301.
184.
YoshidaKNaitoSTakahashiH, Monoamine oxidase: A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(7–8):1279–1283.
185.
KatoMWakenoMOkugawaG, No association of TPH1 218A/C polymorphism with treatment response and intolerance to SSRIs in Japanese patients with major depression. Neuropsychobiology. 2007;56(4):167–171.
186.
WangHCYehTLChangHH, TPH1 is associated with major depressive disorder but not with SSRI/SNRI response in Taiwanese patients. Psychopharmacology (Berl). 2011;213(4):773–779.
187.
GarriockHAllenJDelgadoP, Lack of association of TPH2 exon XI polymorphisms with major depression and treatment resistance. Mol Psychiatry. 2005;10(11):976–977.
188.
HoustonJPLauKArisV, Association of common variations in the norepinephrine transporter gene with response to olanzapine-fluoxetine combination versus continued-fluoxetine treatment in patients with treatment-resistant depression: A candidate gene analysis. J Clin Psychiatry. 2012;73(6):878–885.
189.
BenedettiFColomboCPirovanoA, The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. Psychopharmacology (Berl). 2009;203(1):155–160.
190.
TsaiSJGauYTHongCJ, Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients. J Affect Disord. 2009;113(1–2):183–187.
191.
IlliASetala-SoikkeliEKampmanO, Catechol-O-methyltransferase val108/158met genotype, major depressive disorder and response to selective serotonin reuptake inhibitors in major depressive disorder. Psychiatry Res. 2010;176(1):85–87.
192.
Gudayol-FerreEHerrera-GuzmanICamarenaB, The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder. J Affect Disord. 2010;127(1–3):343–351.
193.
BauneBTHohoffCBergerK, Association of the COMT val158met variant with antidepressant treatment response in major depression. Neuropsychopharmacology. 2008;33(4):924–932.
194.
YoshidaKHiguchiHTakahashiH, Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran. Hum Psychopharmacol. 2008;23(2):121–128.
195.
SzegediARujescuDTadicA, The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J. 2005;5(1):49–53.
196.
XuZZhangZShiY, Influence and interaction of genetic polymorphisms in catecholamine neurotransmitter systems and early life stress on antidepressant drug response. J Affect Disord. 2011;133(1–2):165–173.
197.
YuYWTsaiSJHongCJ, Association study of a monoamine oxidase A gene promoter polymorphism with major depressive disorder and antidepressant response. Neuropsychopharmacology. 2005;30(9):1719–1723.
198.
SerrettiAZanardiRFranchiniL, Pharmacogenetics of selective serotonin reuptake inhibitor response: A 6-month follow-up. Pharmacogenetics. 2004;14(9):607–613.
199.
DomschkeKHohoffCMortensenLS, Monoamine oxidase A variant influences antidepressant treatment response in female patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(1):224–228.
200.
MullerDJSchulzeTGMacciardiF, Moclobemide response in depressed patients: Association study with a functional polymorphism in the monoamine oxidase A promoter. Pharmacopsychiatry. 2002;35(4):157–158.
201.
LavretskyHSiddarthPKumarA, The effects of the dopamine and serotonin transporter polymorphisms on clinical features and treatment response in geriatric depression: A pilot study. Int J Geriatr Psychiatry. 2008;23(1):55–59.
202.
SerrettiAZanardiRCusinC, No association between dopamine D2 and D4 receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors. Psychiatry Res. 2001;104(3):195–203.
203.
GarriockHADelgadoPKlingMA, Number of risk genotypes is a risk factor for major depressive disorder: A case control study. Behav Brain Funct. 2006;2:24.
204.
TsaiSJHongCJChenTJ, Lack of supporting evidence for a genetic association of the FKBP5 polymorphism and response to antidepressant treatment. Am J Med Genet B Neuropsychiatr Genet. 2007;144B(8):1097–1098.
205.
ZobelASchuhmacherAJessenF, DNA sequence variants of the FKBP5 gene are associated with unipolar depression. Int J Neuropsychopharmacol. 2010;13(5):649–660.
206.
SarginsonJELazzeroniLCRyanHS, FKBP5 polymorphisms and antidepressant response in geriatric depression. Am J Med Genet B Neuropsychiatr Genet. 2010;153B(2):554–560.
207.
ZouYFWangYLiuP, Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine. Hum Psychopharmacol. 2010;25(2):145–152.
208.
ChoiMJKangRHLimSW, Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res. 2006;1118(1):176–182.
209.
AlexopoulosGSGlattCEHoptmanMJ, BDNF val66met polymorphism, white matter abnormalities and remission of geriatric depression. J Affect Disord. 2010;125(1–3):262–268.
210.
TaylorWDMcQuoidDRAshley-KochA, BDNF Val66Met genotype and 6-month remission rates in late-life depression. Pharmacogenomics J. 2011;11(2):146–154.
211.
TsaiSJChengCYYuYW, Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am J Med Genet B Neuropsychiatr Genet. 2003;123B(1):19–22.
212.
ZouYFWangYLiuP, Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients. Neuropsychobiology. 2010;61(2):71–78.
213.
XuGLinKRaoD, Brain-derived neurotrophic factor gene polymorphism (Val66Met) and the early response to antidepressant in Chinese Han population. Psychiatr Genet. 2012;22(4):214–215.
214.
YoshidaKHiguchiHKamataM, The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. J Psychopharmacol. 2007;21(6):650–656.
215.
DomschkeKLawfordBLajeG, Brain-derived neurotrophic factor (BDNF) gene: No major impact on antidepressant treatment response. Int J Neuropsychopharmacol. 2010;13(1):93–101.
216.
WilkieMJSmithDReidIC, A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression. Pharmacogenet Genomics. 2007;17(3):207–215.
217.
LicinioJDongCWongML. Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch Gen Psychiatry. 2009;66(5):488–497.
218.
KangRHChangHSWongML, Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. J Psychopharmacol. 2010;24(12):1755–1763.
219.
SerrettiALorenziCCusinC, SSRIs antidepressant activity is influenced by Gbeta3 variants. Eur Neuropsychopharmacol. 2003;13(2):117–122.
220.
KatoMWakenoMOkugawaG, Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(4):1041–1044.
221.
ZillPBaghaiTCZwanzgerP, Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. Neuroreport. 2000;11(9):1893–1897.
222.
LeeHJChaJHHamBJ, Association between a G-protein beta3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders. Pharmacogenomics J. 2004;4(1):29–33.
223.
KeersRBonviciniCScassellatiC, Variation in GNB3 predicts response and adverse reactions to antidepressants. J Psychopharmacol. 2011;25(7):867–874.
224.
KangRHHahnSWChoiMJ, Relationship between G-protein beta-3 subunit C825T polymorphism and mirtazapine responses in Korean patients with major depression. Neuropsychobiology. 2007;56(1):1–5.
225.
GarriockHATanowitzMKraftJB, Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. Am J Psychiatry. 2010;167(5):565–573.
226.
PerlisRHFijalBDhariaS, Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients. Biol Psychiatry. 2010;67(11):1110–1113.
227.
BaghaiTCSchuleCZwanzgerP, Possible influence of the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene on therapeutic outcome in affective disorders. Mol Psychiatry. 2001;6(3):258–589.
228.
BaghaiTCSchuleZillP, The angiotensin I converting enzyme insertion/deletion polymorphism influences therapeutic outcome in major depressed women, but not in men. Neurosci Lett. 2004;363(1):38–42.
229.
BondyBBaghaiTZillP, Genetic variants in the angiotensin I-converting-enzyme (ACE) and angiotensin II receptor (AT1) gene and clinical outcome in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(6):1094–1099.
230.
MendlewiczJOswaldPClaesS, Patient–control association study of substance P-related genes in unipolar and bipolar affective disorders. Int J Neuropsychopharmacol. 2005;8(4):505–513.
231.
HongCJWangYCTsaiSJ. Association study of angiotensin I-converting enzyme polymorphism and symptomatology and antidepressant response in major depressive disorders. J Neural Transm. 2002;109(9):1209–1214.
232.
TsaiSJ. Sipatrigine could have therapeutic potential for major depression and bipolar depression through antagonism of the two-pore-domain K+ channel TREK-1. Med Hypotheses. 2008;70(3):548–550.
233.
SerrettiACalatiRMassatI, Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. Int Clin Psychopharmacol. 2009;24(5):250–256.
234.
AdliMHollindeStammT, Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta −50T/C single nucleotide polymorphism. Biol Psychiatry. 2007;62(11):1295–1302.
235.
CutlerJARushAJMcMahonFJ, Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder. J Psychopharmacol. 2012;26(3):360–367.
236.
Gex-FabryMEapCBOnedaB, CYP2D6 and ABCB1 genetic variability: Influence on paroxetine plasma level and therapeutic response. Ther Drug Monit. 2008;30(4):474–482.
237.
MenuPGressierFVerstuyftC, Antidepressants and ABCB1 gene C3435T functional polymorphism: A naturalistic study. Neuropsychobiology. 2010;62(3):193–197.
238.
RobertsRLJoycePRMulderRT, A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J. 2002;2(3):191–196.
239.
LinKMChiuYFTsaiIJ, ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment. Pharmacogenet Genomics. 2011;21(4):163–170.
